Clear Harbor Asset Management’s Mereo BioPharma MREO Stock Holding History

Clear Harbor Asset Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6K	Hold	35,000	–	–	﹤0.01%	449
2025 Q4	$14.6K	Sell	35,000 -42,000	-55%	-$79.9K	﹤0.01%	443
2025 Q3	$159K	Buy	77,000 +35,000	+83%	+$64.5K	0.01%	402
2025 Q2	$114K	Hold	42,000	–	–	0.01%	398
2025 Q1	$94.5K	Hold	42,000	–	–	0.01%	389
2024 Q4	$147K	Sell	42,000 -1,500	-3%	-$5.89K	0.01%	361
2024 Q3	$179K	Hold	43,500	–	–	0.01%	341
2024 Q2	$157K	Sell	43,500 -2,500	-5%	-$8.1K	0.01%	340
2024 Q1	$152K	Sell	46,000 -13,754	-23%	-$46.6K	0.01%	344
2023 Q4	$108K	Sell	59,754 -4,000	-6%	-$7.65K	0.01%	350
2023 Q3	$82.2K	Buy	63,754 +7,000	+12%	+$9.29K	0.01%	333
2023 Q2	$74.9K	Sell	56,754 -24,000	-30%	-$27.8K	0.01%	343
2023 Q1	$57.1K	Sell	80,754 -3,246	-4%	-$2.92K	0.01%	376
2022 Q4	$63K	Sell	84,000 -61,000	-42%	-$50.1K	0.01%	348
2022 Q3	$125K	Sell	145,000 -17,000	-10%	-$20.8K	0.02%	333
2022 Q2	$186K	Buy	162,000 +138,500	+589%	+$107K	0.02%	331
2022 Q1	$26K	Buy	23,500 +6,500	+38%	+$8.41K	﹤0.01%	395
2021 Q4	$27K	Buy	+17,000	New	+$34K	﹤0.01%	411

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Clear Harbor Asset Management's MREO Position: Q1 2026 in Review

Clear Harbor Asset Management held its Mereo BioPharma (MREO) position steady in Q1 2026 at 35,000 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #449.

Clear Harbor Asset Management first reported a position in MREO in Q4 2021 and has held it in 18 quarters since. The position peaked at $186K in Q2 2022. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

Clear Harbor Asset Management held 35,000 shares of Mereo BioPharma worth $11.6K as of Q1 2026.
Clear Harbor Asset Management left its Mereo BioPharma share count unchanged in Q1 2026.
Mereo BioPharma made up ﹤0.01% of Clear Harbor Asset Management's portfolio in Q1 2026, its #449 holding.
Clear Harbor Asset Management first reported a position in Mereo BioPharma in Q4 2021 and has held it in 18 quarters since.
Clear Harbor Asset Management's Mereo BioPharma position peaked at $186K in Q2 2022.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Clear Harbor Asset Management's 13F filing for Q1 2026, filed 5 May 2026.